2Nevitt GJ Hutchinson. Psoriasis in the Community: prevalance,severity and patients, beliefs and attitudes towards the disease[J]. Br J Dermatol, 1996,135(4) :533-537.
3Valdimarsson H,Baker BS,Jonsdottir L,et al.Psoriasis:a disease of abnormal keratinocyte proliferation induced by T lymphocyte[J].Immunol Today,1986,7:257-259.
4Baker BS, Fry L. The Immunity of Psoriasis[J]. Br J Dermatol, 1992,126:1.
5Bos JD, De Rie MA.The Pathogenosis of Psoriasis:immunological facts and speculation[j].Immunology Today,1999,20(1):40-46.
6Gupta AM,Gupta AK,Kirkby S,et al.Pruitus in Psoriasis[J].Arch Dermatol. 1988,124:1052.
7Fleisehmajer R. The study of MMP-2,TIMP-2 in psoriatic and non-psoriatic skin[J].J Invest Dermatol,2000,115(5):771-777.
8Yoshizaki T, Maruyama Y, Sato H,et al.Expression of tissue inhibitor of MMP-2 correlates with activation of MMP-2 and predicts poor prognosis in tongue squamous cell carcinoma[J].Int J Cancer,2001,95:44-50.
9Vasku V,Vasku A,Tschoplova,et al.Genotype association of c(-735) T polymorphism in MMP-2 gene with G(8002)A endothelin, gene with plaque psoriasis[J].Dermatology,2002,204(4):262-265.
10Sawa M,Tsukamoto T,kiyoi T,et al.New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs[J].J Med Chem,2002,45(4):930-936.
